General contact

Main switchboard
Switzerland

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 a.m. - 5:00 p.m. GMT+1

US switchboard

+1 862 778 21 00
Monday - Friday,
8:30 a.m. - 5:00 p.m. EST

Media

Global Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

Investors

Investor Relations
Switzerland

Monday - Friday,
8:30 a.m. - 5:30 p.m. GMT+1
(Central European Time)

Reporting side effects

Report a suspected side effect (also known as an adverse event) related to a Novartis Pharmaceutical drug or a Novartis Vaccine.

Reporting side effects

pane 4 content

Healthcare portfolio

Novartis has five business segments and is supported by our global research organization, the Novartis Institutes for BioMedical Research (NIBR). These segments are strategically aligned to bring innovative, high-quality and affordable medicines and therapies to patients around the world.

Making full use of its cross-divisional cooperation potential, Novartis continually looks for opportunities to leverage the strength of its global and diverse businesses to meet patient needs and extend its differentiated leadership position.

We continuously evolve our businesses to create a patient-centered portfolio consisting of a wide range of products and treatments to address unmet medical needs.

enlarge

  1. In January 2014, Novartis completed the divestment of its blood transfusion diagnostics unit to Grifols for USD 1.7 billion.